-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FvDJYUrdyHwV0VZAAo6hWTOsHZsyilm6UYZBaj+TiwmFhH81y0LDo1nMmAuReLix aHRLyGAK0wXmlqWer8w7yg== 0000000000-09-006704.txt : 20090323 0000000000-09-006704.hdr.sgml : 20090323 20090209111833 ACCESSION NUMBER: 0000000000-09-006704 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090209 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908 541 8671 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 STREET 2: ATT: GENERAL COUNSEL CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 PUBLIC REFERENCE ACCESSION NUMBER: 0000950123-08-002345 LETTER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH-/#PO3&EN96%R:7IE9"`Q+TP@-S0Y M-B]/(#@O12`S,CDV+TX@,2]4(#!BZ=1];Y*6%?2!K``(P,# MCPM4FQ40LS(P2`M"Q!E>`P08`%*Y!Z`-"F5N9'-T7!E+T-A=&%L M;V7!E+U!A9V4^/@UE;F1O8FH-.2`P(&]B:@T\/"]&;VYT/#PO5%0R(#$P M(#`@4B]45#0@,3(@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'1=+T5X=$=3=&%T M93P\+T=3,2`Q-2`P(%(^/CX^#65N9&]B:@TQ,"`P(&]B:@T\/"]3=6)T>7!E M+U1R=654>7!E+T9O;G1$97-CM%5-<]HP$+WS M*_8H=;`B&?R56[[H-)FDF>"FT\GTH!@!;L'."),T_?5=2;:`0-OIH3!8:]F[ M^][;77'T?BQ@MNJ=YKVC/`]!0#[MB1`X?G')."0\95D,^;+'88:_O#"7EQX! MFG]#,Q!,1)"?MQOYNW\S&.<\,4&#UGKI/9#[4L)(%JMR25,6D7*A0%83^,3& M#*YEN0#Z-;\TWEMP[/ZXJ9\@YH(?2/B?/R/UJ-=2OT+4G6#<*F88 MIYY[ZKB?:5G.X(1!7M>&?DQDY?A:5PS<>GK51.8\+WZH8MV4SPKN:<(R4E)\ M/R*%@ENM5G1HMB:JHA%+2-.'45G)JG#*;L?_`[1YJ:9TP%+2.I=R`1_=CKO: ME$-,J?<@([[J9UW![5SJEE>A$&XA%ZL^8L*@'ZJ"'88R\%`&MMAQ&L%=O6X4 M2AT>A3S>:.NRV7=#X]4:Z'2JR\E,OI'!ZW:ECTQG(&_EFI*:!J4$KP1;[?>)=R/#M9``-PC#B6-91K9<@ M>'`%TUI#,U=8DQ6&@R]*:LPY41,X5X5:/F(Q!L(V9;*O;N#U\<')"`=NXAJ: MQEA.25E(L+/#S$9)]Z!N1-L-`C=KDQY5P"2!"+,HL:Y;1\V`83R^D3=P.R9T MNJ6ZTWJPM^,'R8O?:G]N5+C69HQH3.PDI3A)QUW^MH8)B\+(Y7];^0W(P+UU M&($O?^1K%6V42%`)^$PS-B"*!CAX,)B[5"]13"T[$ M+!TX2`=:'\.^&A]3?N0DB.D!&L08^LJ.LHU?U3!=:VR*=@X#%W0'[Z:WVO(C MJ*6JFA7(!ONI7$%CSE^#6Q!VZ,C=.EM;*V2)E>'!'[=CBAH([)\2C6&"1:BH M5:4P]Z8HJC.T->Q]9`Z31>?QZCSZ;ME%LO^/TF'8G/CF03C<93_T[(>6RV6M M%G`K]7G#;8?$``J1F^?BC=IA7;NEI=QTA-YJ,>N8X1*14QNV MDT-V(=_J-M]RXN3,.;6;/H$77!E+T9O;G0^/@UE;F1O8FH-,3,@,"!O8FH-/#PO4W1E;58@ M.#(O1F]N=$YA;64O5&EM97-.97=2;VUA;E!3350O1F]N=%-T%LM-38X("TS,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$97-C%LM-34X("TS,#<@,C`P,"`Q M,#(V72]!7!E+T9O;G1$97-C'1'4W1A=&4O4T$@9F%L7!E+UA-3"],96YG=&@@,S8P,R]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_ M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S$V(#0T+C(U,SDR,2P@4W5N M($]C="`P,2`R,#`V(#$W.C$T.C,Y(CX*("`@/')D9CI21$8@>&UL;G,Z&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT"UD969A M=6QT(CY-:6-R;W-O9G0@5V]R9"`M($5N>F]N3D9#;&5T=&5R+F1O8SPO&UL;G,Z>&%P/2)H='1P M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!6 M97)S:6]N(#4N,BXR/"]X87`Z0W)E871O&%P34TZ26YS=&%N8V5)1#YU=6ED.C$Y,#4U-V%F+3AE9#0M M-#%F,RUB-C-C+3=E9&(T-&)B,S,S83PO>&%P34TZ26YS=&%N8V5)1#X*("`@ M("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO -----END PRIVACY-ENHANCED MESSAGE-----